〔Abstract〕 Objective To explore the clinical effect of SperMagic on azoospermia patients during intracytoplasmic sperm microinjection (ICSI). Methods From January 2019 to January 2021, 200 patients with azoospermia in the transplantation cycle admitted to the Foshan Maternal and Child Health Hospital were selected, and the subjects were randomly divided into observation group and control group, with 100 cases in each group, following the random number table method. The control group received ICSI after sperm processing, and the observation group received the sperm agonist SperMagic after sperm processing. The differences in sperm motility and assisted reproduction outcomes between the two groups of patients were compared. Results After corresponding treatment of sperm, the sperm motility of the observation group was (92.6 ± 3.6)%, which was statistically significant (P < 0.05) compared with the sperm motility of the control group (67.6 ± 11.4)%. Compared with the control group, the observation group had significantly better assisted reproduction outcomes such as fertilization rate, excellent embryo rate, implantation rate, pregnancy rate and abortion rate, and the differences were statistically significant (P < 0.05). Conclusion Adding sperm agonist SperMagic to ICSI can significantly increase sperm motility and improve pregnancy outcome.